Mabwell(SH:688062) Xin Lang Cai Jing·2025-11-07 06:30Group 1 - The core point of the news is that Maiwei Biotech's stock price has dropped by 5.01%, currently trading at 42.24 CNY per share, with a total market capitalization of 16.879 billion CNY [1] - Maiwei Biotech, established on May 12, 2017, and listed on January 18, 2022, focuses on the research, production, and sales of therapeutic biological products, with 99.91% of its revenue coming from product sales [1] - The trading volume for Maiwei Biotech reached 256 million CNY, with a turnover rate of 2.90% [1] Group 2 - Southern Fund's Southern CSI 1000 ETF (512100) has entered the top ten circulating shareholders of Maiwei Biotech, holding 2.1906 million shares, which is 1.07% of the circulating shares [2] - The estimated floating loss for the Southern CSI 1000 ETF today is approximately 4.885 million CNY [2] - The Southern CSI 1000 ETF was established on September 29, 2016, with a current scale of 76.63 billion CNY and has achieved a year-to-date return of 28.25% [2] Group 3 - The fund manager of Southern CSI 1000 ETF is Cui Lei, who has been in the position for 7 years and 2 days, managing a total asset scale of 122.76 billion CNY [3] - During Cui Lei's tenure, the best fund return was 176.39%, while the worst return was -15.93% [3]